Sarepta Therapeutics (SRPT) calls active into EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Baird Reiterates Outperform on Sarepta Therapeutics (SRPT)
August 9, 2018 9:06 AM EDTBaird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales come in ahead of expectations at $73.5M vs. consensus estimate of $71.0M, a $8.9 sequential increase over 1Q18. Sales continue to track towards the... More
